INTRODUCTION
============

According to data published by the Korean Diabetes Association in 2018, one in seven (14.4%) Koreans over 30 years old had diabetes in 2016 \[[@b1-enm-2020-35-2-319]\]. Diabetes is a chronic disease that leads to retinopathy, nephropathy, cardiovascular disease, stroke, and other serious complications. High blood glucose levels are the main factor in the development of these complications and are also associated with increased mortality \[[@b2-enm-2020-35-2-319],[@b3-enm-2020-35-2-319]\].

Glycemic variability is the physiological consequence of both carbohydrate intake and the circadian rhythms of hormones involved in the regulation of glucose metabolism \[[@b4-enm-2020-35-2-319]\]. Glycemic variability is known to be high in people with diabetes, especially in those with low body mass index (BMI) values \[[@b5-enm-2020-35-2-319]\].

To prevent diabetic complications, it is crucial to maintain proper blood glucose levels. To accomplish this goal, hemoglobin A1c (HbA1c), fasting plasma glucose, and postprandial blood glucose levels should be maintained within target ranges \[[@b6-enm-2020-35-2-319]\].

Recently, the clinical significance of glucose variability has been highlighted in the context of the three aforementioned indicators \[[@b7-enm-2020-35-2-319]\]. Even among patients with similar HbA1c levels, fluctuations of blood glucose during the day can vary \[[@b8-enm-2020-35-2-319]\]. Similarly to fasting glucose, postprandial glucose, and HbA1c levels, diurnal variation in blood glucose levels is associated with the incidence of complications, with a large magnitude of variation associated with increased risk \[[@b9-enm-2020-35-2-319]\]. Therefore, it is important to reduce the diurnal variation of glucose in patients with diabetes \[[@b10-enm-2020-35-2-319],[@b11-enm-2020-35-2-319]\].

Blood glucose can be measured using a continuous glucose monitoring system (CGMS) to evaluate diurnal glucose variability \[[@b12-enm-2020-35-2-319]\]. However, this system is not yet widely applied in clinical settings because the equipment is expensive and uncomfortable to wear \[[@b13-enm-2020-35-2-319]\]. Furthermore, the values measured by CGMS and its target range have yet to be standardized, limiting the usage of CGMS \[[@b6-enm-2020-35-2-319]\].

The hemoglobin glycation index (HGI) is another indicator that can be easily used in clinical settings to assess fluctuations in blood glucose. As an indicator of blood glucose metabolism relevant to diabetic complications, the HGI reflects diurnal variation in glucose levels \[[@b14-enm-2020-35-2-319]\]. A previous study reported that a high HGI was associated with an increased risk of cardiovascular complications such as coronary artery disease, stroke, and peripheral arterial disease in patients with pre-diabetes or diabetes \[[@b15-enm-2020-35-2-319]\]. The HGI has also been reported to be associated with an increased risk of coronary artery calcification in patients without diabetes, irrespective of HbA1c levels \[[@b16-enm-2020-35-2-319]\].

Thigh and waist circumference are physical measurements that are strongly associated with diabetes risk. As thigh circumference increases, the risk of diabetes is reduced \[[@b17-enm-2020-35-2-319]\], and as it decreases, the risk of diabetes increases \[[@b18-enm-2020-35-2-319]\]. Thigh circumference is also known to be independently associated with insulin resistance in patients with type 2 diabetes \[[@b19-enm-2020-35-2-319]\].

In contrast, increased waist circumference is associated with an increased risk of diabetes \[[@b17-enm-2020-35-2-319]\]. This relationship exists because waist circumference is an indicator of central obesity \[[@b20-enm-2020-35-2-319]\], which is strongly correlated with insulin resistance \[[@b21-enm-2020-35-2-319],[@b22-enm-2020-35-2-319]\].

Although thigh and waist circumference are associated with the incidence of diabetes, and the HGI is known to be a major factor in the prediction of diabetic complications, little is known about the relationships of thigh and waist circumference with the HGI. The main purpose of this study was to investigate this relationship. Furthermore, we sought to understand the relationship between thigh circumference and the presence of carotid artery plaque, which is a cardiovascular complication of diabetes.

METHODS
=======

Subjects
--------

This cross-sectional survey study included 3,075 patients with diabetes (male, 1,569; female, 1,506) who were admitted to Huh's Diabetes Center in Seoul between September 2002 and October 2016. The subjects of this study were patients with type 2 diabetes who underwent carotid ultrasonography. To exclude the possibility of type 1 diabetes, we included only patients over 30 years old with negative anti-glutamic acid decarboxylase antibody tests and with C-peptide levels higher than 0.6 ng/mL. Furthermore, we included only patients for whom all variables required for the analysis had been evaluated. The study protocol was approved by the Institutional Review Board/Ethics Committee (IBR No.: 2019-I077) of Hallym University Sacred Heart Hospital. Informed written consent was obtained from all participants.

Measurements
------------

All anthropometric values were measured with patients barefoot and wearing only light clothes \[[@b23-enm-2020-35-2-319]\]. BMI (kg/m^2^) was calculated using measured height and weight. Using a tape measure, waist circumference was measured after exhalation at the level midway between the lowest rib margin and the iliac crest. Thigh circumference was measured directly below the gluteal fold at the left leg, and calf circumference was measured at the thickest part of the calf.

At their first visit, all patients underwent measurements of systolic blood pressure, diastolic blood pressure, and levels of fasting blood glucose (FPG), HbA1c, C-peptide, blood insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. We evaluated the extent of insulin resistance and β-cell dysfunction using homeostatic model assessment for insulin resistance (HOMA-IR) and β-cell dysfunction (HOMA-B) calculated from fasting glucose and insulin levels using the formulas HOMA-IR=\[glucose (mg/dL)×insulin (μU/mL)\]/405 and HOMA-B=\[20×insulin (μU/mL)\]/\[glucose (mg/dL)/18--3.5\].

Participants' age, sex, hypertension status, duration of diabetes, lifestyle factors (drinking, smoking, and exercise status), and medication usage (hypoglycemic agents, antihypertensive agents, or statins) were examined using questionnaires. Carotid ultrasonography was conducted with a 10-MHz high-resolution carotid ultrasound device with a linear probe (LOGIQ 7, GE Healthcare, Milwaukee, WI, USA). The carotid arteries on both sides were observed, and a carotid plaque was defined as a distinctly hyperechoic lesion or a localized protrusion of the vessel wall with a thickness exceeding the intima-media thickness of the adjacent portion of the vessel wall by \>50% \[[@b24-enm-2020-35-2-319]\].

Calculation of the HGI
----------------------

The HGI can be expressed as the difference between the measured HbA1c and the predicted HbA1c \[[@b25-enm-2020-35-2-319]\]. To calculate the predicted HbA1c, a formula described in a previous study (predicted HbA1c=0.030×FPG+2.978) was used \[[@b15-enm-2020-35-2-319]\]. The greater the HGI, the greater the difference between the predicted HbA1c and the measured HbA1c. When the HGI value was zero or greater, we defined it as a positive HGI.

Statistical analyses
--------------------

All continuous variables were expressed as mean±standard deviation, and nominal variables were expressed as percentages. First, subjects were grouped by sex. Then, each group was classified into four quartiles (Q1 through Q4) by both thigh circumference and waist circumference. To minimize the effect of measurement errors, each group was partitioned at appropriate intervals. For each group, the odds ratios (ORs) for a positive HGI and the existence of carotid plaque were computed via logistic regression. The group with the smallest measurement values (Q1) was used as a reference for both comparisons. We constructed four models in total: one unadjusted model and three adjusted multiple logistic regression models. Each adjusted model had different adjustment schemes. The first model was adjusted for age and duration of diabetes, while the second was additionally adjusted for BMI. In addition to age, diabetes duration, and BMI, the third model was adjusted for systolic blood pressure, exercise status, smoking status, use of hypoglycemic agents (insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitors, glitazones, dipeptidyl peptidase-4 inhibitors, or sodium-glucose cotransporter 2 inhibitors), high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, triglyceride level, and statin usage. The ORs of each model were expressed as values with 95% confidence intervals. All statistical analyses were performed using R software version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). *P* values \<0.05 were considered to indicate statistical significance.

RESULTS
=======

Baseline characteristics
------------------------

The baseline characteristics of the participants are described in [Table 1](#t1-enm-2020-35-2-319){ref-type="table"}. The average age of the entire study sample was 58.6 years for men and 60.7 years for women, while the average duration of diabetes was 8.3 years for men and 8.5 years for women. The overall average circumferences of the thigh and waist were 44.5 cm (men, 45.2; women, 43.8) and 84.1 cm (men, 87.1; women, 81.0), respectively. [Table 2](#t2-enm-2020-35-2-319){ref-type="table"} shows the baseline clinical characteristics of male and female patients classified by thigh circumference.

Characteristics of participants according to thigh circumference
----------------------------------------------------------------

In men, in addition to BMI and waist circumference, insulin resistance, insulin secretion ability (as shown by C-peptide levels and HOMA-B) \[[@b26-enm-2020-35-2-319]\], and triglyceride levels increased as thigh circumference increased. A similar trend was evident in women ([Table 2](#t2-enm-2020-35-2-319){ref-type="table"}).

Relative risk of a positive HGI according to thigh and waist circumference
--------------------------------------------------------------------------

After adjustment, we observed that the larger the thigh circumference, the smaller the risk of a positive HGI in men. In contrast, no difference in blood glucose variability was observed according to thigh circumference in women ([Table 3](#t3-enm-2020-35-2-319){ref-type="table"}). In men, no difference in the HGI according to waist circumference was observed. However, in women, the larger the waist circumference, the higher the chance of a positive HGI even after adjustment ([Table 4](#t4-enm-2020-35-2-319){ref-type="table"}).

We additionally divided patients into four groups by their waist-to-thigh circumference ratio to determine whether a relationship existed between HGI and the combination of thigh and waist circumference. After adjustment for potential confounding variables, the risk of a positive HGI was found to be higher when waist circumference was larger and thigh circumference was smaller ([Fig. 1](#f1-enm-2020-35-2-319){ref-type="fig"}).

The risk of carotid plaque according to thigh circumference and waist circumference
-----------------------------------------------------------------------------------

In men, it was found that the larger the thigh circumference, the lower the risk of carotid plaque after adjustment for potential confounding variables. In women, a similar tendency was observed before adjustment, but no statistically significant relationship was seen after adjustment ([Table 5](#t5-enm-2020-35-2-319){ref-type="table"}). In men, no difference in the presence of carotid plaque according to waist circumference was observed. In women, the presence of carotid plaque was higher in the thickest waist group compared to the reference group, but there is no statistical significance after adjustment ([Table 6](#t6-enm-2020-35-2-319){ref-type="table"}).

DISCUSSION
==========

The clinical significance of blood glucose variability in the development of diabetic complications has been recognized. Many parameters have been introduced to represent blood glucose variability, such as the mean amplitude of glycemic excursions \[[@b27-enm-2020-35-2-319]\], M-value \[[@b22-enm-2020-35-2-319]\], lability index \[[@b28-enm-2020-35-2-319]\], composite hypoglycemic score \[[@b28-enm-2020-35-2-319]\], average daily risk range \[[@b29-enm-2020-35-2-319]\], and others. In our study, we used the HGI as an indicator of blood variability that can be easily used in clinical settings. The HGI has also been reported to be associated with diabetic complications \[[@b14-enm-2020-35-2-319]\].

The results of this study showed that men with type 2 diabetes were significantly less likely to exhibit a positive HGI as their thigh circumference increased. In contrast, no relationship was found between the risk of a positive HGI and thigh circumference in women. As many muscles in our body are located in the thigh region, this result suggests that muscle mass impacts the HGI more strongly in men than in women.

In contrast, in women, the larger the waist circumference, the greater the risk of a positive HGI (a tendency not shown in men). In contrast to the aforementioned results based on thigh circumference, this indicates that the amount of fat has a greater effect on the HGI in women than in men.

As the waist-to-thigh circumference ratio increased, the likelihood of a positive HGI also increased in both men and women. This indicates that both muscle mass and fat mass contribute to the presence of a positive HGI.

We observed clear correlations between thigh and waist circumference and the HGI in both men and women; however, in men, thigh circumference had a stronger correlation with the HGI than waist circumference, while the opposite was true in women. In other words, in the development of HGI in men, muscle appears to be more important than fat, while in women, fat appears to play a greater role than muscle. This may be because men have more muscle mass and less fat than women. To reduce the risk of complications caused by a high HGI, it is important to emphasize the importance of a high thigh circumference in men and a low waist circumference in women.

In men, the smaller the thigh circumference, the higher the likelihood of carotid plaque. This tendency was not seen in women, which may be because men have a higher risk of arteriosclerosis than women.

In this study, the risk of a positive HGI increased as thigh circumference decreased in men and as waist circumference increased in women. In addition, the larger the thigh circumference, the lower the risk of carotid plaque in men.

In terms of identifying risk factors for diabetes, cross-sectional studies such as the present study cannot determine the causal nature of relationships, as the temporality of relationships is difficult to establish \[[@b30-enm-2020-35-2-319]\]. Therefore, a prospective study is required for the accurate evaluation of thigh and waist circumference and blood glucose variability. In addition, it is necessary to investigate the most suitable cut-off values of thigh circumference, waist circumference, and waist-to-thigh circumference ratio for the purposes of predicting the HGI and reducing complications.

The study examined only the relationship between thigh circumference and the presence of carotid plaque. However, if further studies identify additional relationships between physical measurements and complications, indicators that can be more easily applied in clinical settings (e.g., BMI) may be discovered. As a final limitation, the subjects of this study were limited to patients at a single medical center in Seoul, so the results are unlikely to apply to all type 2 diabetes patients.

Nevertheless, many risk factors are combined in chronic diseases such as diabetes, and as they have an unclear pathogenesis \[[@b30-enm-2020-35-2-319]\], more studies should be conducted to examine various factors in a similar fashion to this study. The present study is also meaningful because the primary indicators (namely thigh circumference and waist circumference) are familiar to patients  and can be easily measured in clinical practice.

This paper is dedicated to the memory of our wonderful colleague and eternal master, devoting his life to studying diabetes, Professor Kap Bum Huh, who passed away in January 23, 2020.
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###### 

Baseline Clinical Characteristics of Participants

  Characteristic                       Total        Men          Women
  ------------------------------------ ------------ ------------ ------------
  Number                               3,075        1,569        1,506
                                                                 
  Age, yr                              58.6±10.2    56.7±10.8    60.7±9.1
                                                                 
  DM duration, yr                      8.3±7.9      8.2±7.9      8.5±7.8
                                                                 
  SBP, mm Hg                           131.8±17.0   130.9±16.2   132.7±17.7
                                                                 
  Hypertension (yes), %                38.2         34.0         42.7
                                                                 
  Use of antihyperglycemic agents, %                             
   Insulin                             10.6         8.9          12.4
   Sulfonylurea                        49.6         48.3         50.9
   Biguanide                           54.6         51.2         58.1
   α-Glucosidase inhibitor             9.7          9.6          9.9
   Glitazone                           7.8          8.1          7.5
   DPP4 inhibitor                      12.6         12.1         13.1
   SGLT2 inhibitor                     0.2          0.3          0.1
                                                                 
  Statin usage, %                      23.9         19.1         29
                                                                 
  Exercise (yes), %                    67.3         68.6         65.9
                                                                 
  Smoker (current), %                  14.5         26.4         2.0
                                                                 
  Smoker (ex), %                       25.1         47.4         1.9
                                                                 
  BMI, kg/m^2^                         24.3±2.9     24.6±2.7     24.1±3.1
                                                                 
  Waist circumference, cm              84.1±8.2     87.1±7.3     81.0±7.8
                                                                 
  Hip circumference, cm                92.6±5.2     93.8±4.9     91.4±5.3
                                                                 
  Thigh circumference, cm              44.5±3.6     45.2±3.5     43.8±3.5
                                                                 
  Leg circumference, cm                34.7±2.9     36.0±2.7     33.3±2.4
                                                                 
  Fasting plasma glucose, mg/dL        156.6±50.7   160.6±52.2   151.7±48.8
                                                                 
  HbA1c, %                             7.9±1.7      7.9±1.8      7.8±1.7
                                                                 
  Hemoglobin glycation index           0.22±1.25    -0.06±1.24   0.07±1.18
                                                                 
  C-peptide, ng/mL                     2.05±0.94    2.07±0.89    2.03±0.99
                                                                 
  Total cholesterol, mg/dL             187.9±41.0   185.6±41.0   190.4±40.8
                                                                 
  Triglyceride, mg/dL                  135.9±80.5   140.9±84.6   130.7±75.7
                                                                 
  HDL-C, mg/dL                         49.3±12.1    46.9±10.9    51.8±12.7
                                                                 
  LDL-C, mg/dL                         111.3±35.9   110.3±35.9   112.3±36.0
                                                                 
  HOMA-IR                              2.9±1.9      2.8±1.8      3.0±2.1
                                                                 
  HOMA-B                               37.7±28.3    34.2±26.3    41.4±29.9

Values are expressed as mean±standard deviation.

DM, diabetes mellitus; SBP, systolic blood pressure; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; HOMA-B, homeostatic model assessment of β-cell function.

###### 

Baseline Clinical Characteristics According to Quartile of Thigh Circumference in Men and Women

  Characteristic                        Q1           Q2           Q3           Q4
  ------------------------------------- ------------ ------------ ------------ -------------
  Men (*n*=1,569)                                                              
  Thigh, cm                             36--40       41--45       46--50       51--55
   Number of subjects                   147          709          545          168
   Age, yr                              63.1±10.0    59.2±10.1    54.5±10.0    47.9±9.8
   DM duration, yr                      12.5±9.4     9.2±8.3      6.7±6.8      5.1±5.8
   Systolic blood pressure, mm Hg       129.0±18.4   130.6±17.0   131.5±14.9   131.6±14.7
   Hypertension (yes), %                26.5         36.2         33.4         32.7
   Use of antihyperglycemic agents, %                                          
    Insulin                             10.9         10.2         7.3          7.1
    Sulfonylurea                        50.3         50.2         48.4         38.1
    Biguanide                           55.1         55.6         48.4         38.1
    α-Glucosidase inhibitor             16.3         11.6         7.3          2.4
    Glitazone                           3.4          8.9          8.6          7.1
    DPP4 inhibitor                      13.6         13.3         10.8         10.1
    SGLT2 inhibitor                     0            0.1          0.2          1.2
   Statin usage, %                      17.7         19.3         19.3         18.5
   Exercise (yes), %                    63.3         75.3         65.5         55.4
   Smoker (current), %                  23.8         23.8         30.5         26.8
   Smoker (ex), %                       44.2         48.7         47.5         44.6
   BMI, kg/m^2^                         21.2±2.1     23.6±1.9     25.7±2.0     27.9±2.4
   Waist circumference, cm              80.1±6.7     85.1±6.4     89.6±6.2     93.2±6.9
   Hip circumference, cm                87.9±3.5     92.1±3.5     95.9±4.00    99.5±4.2
   Thigh circumference, cm              38.8±1.3     43.4±1.3     47.3±1.1     51.3±1.4
   Leg circumference, cm                32.8±1.9     35.1±1.9     37.1±2.1     39.5±2.2
   Waist-to-thigh ratio, cm/cm          1.82±0.13    1.90±0.13    1.96±0.13    2.04±0.14
   Fasting plasma glucose, mg/dL        169.5±70.8   159.6±49.9   158.6±47.8   163.6±55.3
   HbA1c, %                             8.2±2.3      7.8±1.6      8.0±1.8      8.0±1.8
   Hemoglobin glycation index           −0.04±1.59   −0.13±1.19   0.03±1.24    −0.10±1.10
   C-peptide, ng/mL                     1.82±0.92    1.98±0.91    2.13±0.78    2.49±1.01
   Total cholesterol, mg/dL             181.0±43.2   182.6±40.4   187.9±39.3   194.4±45.5
   Triglyceride, mg/dL                  108.0±62.2   133.1±77.1   149.7±83.0   174.1±116.6
   HDL-C, mg/dL                         49.7±11.6    47.6±11.4    45.9±9.8     44.5±10.4
   LDL-C, mg/dL                         108.6±38.2   107.9±34.5   112.4±36.2   115.5±37.6
   HOMA-IR                              2.5±1.5      2.7±1.6      2.9±1.8      3.6±2.4
   HOMA-B                               29.0±24.5    32.5±24.9    35.7±26.0    41.1±31.9
                                                                               
  Women (*n*=1,506)                                                            
   Thigh, cm                            34--39       40--43       44--47       48--53
   Number of subjects                   154          571          568          213
   Age, yr                              63.6±9.2     62.2±8.3     59.6±9.1     57.3±9.5
   DM duration, yr                      11.1±8.6     9.8±8.3      7.4±7.1      5.9±6.5
   Systolic blood pressure, mm Hg       128.4±18.4   133.2±18.0   132.5±16.9   135.1±18.2
   Hypertension (yes), %                35.1         41.9         43.7         47.9
   Use of antihyperglycemic agents, %                                          
    Insulin                             11.7         14.2         12           8.9
    Sulfonylurea                        53.2         54.3         49.3         44.1
    Biguanide                           56.5         61.6         56.5         54
    α-Glucosidase inhibitor             13           11           8.6          8
    Glitazone                           6.5          6.7          8.6          7.5
    DPP4 inhibitor                      17.5         11.7         13.9         11.3
    SGLT2 inhibitor                     0            0.2          0.2          0
   Statin usage, %                      24.7         31.2         28.7         26.8
   Exercise (yes), %                    66.2         69.7         65.3         57.3
   Smoker (current), %                  3.2          1.9          1.9          1.4
   Smoker (ex), %                       1.9          1.4          2.3          1.9
   BMI, kg/m^2^                         21.0±3.1     22.9±2.4     24.9±2.3     27.5±2.6
   Waist circumference, cm              75.0±7.2     78.9±7.2     82.4±7.1     87.0±6.5
   Hip circumference, cm                86.3±3.4     89.1±3.9     92.8±4.4     97.2±4.9
   Thigh circumference, cm              37.9±1.2     41.7±1.1     45.3±1.1     49.4±1.5
   Leg circumference, cm                30.3±1.4     32.1±1.7     34.1±1.8     36.2±1.8
   Waist-to-thigh ratio, cm/cm          1.70±0.13    1.83±0.13    1.88±0.13    1.99±0.16
   Fasting plasma glucose, mg/dL        156.1±51.9   151.2±49.4   150.6±45.8   152.9±52.9
   HbA1c, %                             8.1±2.0      7.8±1.6      7.8±1.7      7.8±1.6
   Hemoglobin glycation index           0.17±1.30    0.06±1.19    0.07±1.2     0.00±1.04
   C-peptide, ng/mL                     1.83±1.17    1.88±0.86    2.14±1.06    2.30±0.88
   Total cholesterol, mg/dL             184.1±41.5   190.7±41.9   189.9±39.6   195.6±40.3
   Triglyceride, mg/dL                  120.1±78.7   125.5±73.3   135.5±79.8   139.6±66.9
   HDL-C, mg/dL                         52.7±14.7    52.6±13.0    51.4±12.1    50.3±12.1
   LDL-C, mg/dL                         107.0±35.0   112.9±36.6   111.3±35.7   117.4±34.9
   HOMA-IR                              2.6±1.7      2.9±2.0      3.1±2.1      3.6±2.6
   HOMA-B                               34.8±27.1    39.5±28.7    42.5±29.8    48.1±33.9

Values are expressed as range or mean±standard deviation.

Q, quartile; DM, diabetes mellitus; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; HOMA-B, homeostatic model assessment of β-cell function.

###### 

HGI According to Quartile of Thigh Circumference in Men and Women

  Variable                                                                  Q1      Q2                                                                      Q3                                                                       Q4
  ------------------------------------------------------------------------- ------- ----------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------
  Men                                                                                                                                                                                                                                
   Number of subjects                                                       147     709                                                                     545                                                                      168
   Positive HGI                                                                                                                                                                                                                      
    Unadjusted OR                                                           1.000   0.825 (0.577--1.177)                                                    0.903 (0.626--1.300)                                                     0.711 (0.455--1.108)
    Adjusted OR (95% CI)[a](#tfn6-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.751 (0.522--1.078)                                                    0.747 (0.509--1.092)                                                     0.523 (0.324--0.841)[e](#tfn10-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[b](#tfn7-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.641 (0.437--0.937)[d](#tfn9-enm-2020-35-2-319){ref-type="table-fn"}   0.548 (0.350--0.855)[e](#tfn10-enm-2020-35-2-319){ref-type="table-fn"}   0.329 (0.182--0.591)[f](#tfn11-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[c](#tfn8-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.670 (0.452--0.989)[d](#tfn9-enm-2020-35-2-319){ref-type="table-fn"}   0.569 (0.360--0.896)[d](#tfn9-enm-2020-35-2-319){ref-type="table-fn"}    0.349 (0.190--0.637)[f](#tfn11-enm-2020-35-2-319){ref-type="table-fn"}
                                                                                                                                                                                                                                     
  Women                                                                                                                                                                                                                              
   Number of subjects                                                       154     571                                                                     568                                                                      213
   Positive HGI                                                                                                                                                                                                                      
    Unadjusted OR                                                           1.000   1.039 (0.722--1.489)                                                    0.979 (0.680--1.402)                                                     0.991 (0.650--1.508)
    Adjusted OR (95% CI)[a](#tfn6-enm-2020-35-2-319){ref-type="table-fn"}   1.000   1.060 (0.736--1.521)                                                    1.036 (0.716--1.493)                                                     1.083 (0.703--1.666)
    Adjusted OR (95% CI)[b](#tfn7-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.970 (0.666--1.407)                                                    0.860 (0.569--1.295)                                                     0.797 (0.470--1.348)
    Adjusted OR (95% CI)[c](#tfn8-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.954 (0.650--1.394)                                                    0.866 (0.569--1.311)                                                     0.826 (0.482--1.410)

HGI, hemoglobin glycation index; Q, quartile (Q1 was the lowest quartile); OR, odds ratio; CI, confidence interval.

Adjusted for age and duration;

As in ^a^, and additionally adjusted for body mass index;

As in ^b^, and additionally adjusted for systolic blood pressure, exercise status, smoking status, hypoglycemic agent usage (insulin, sulfonylurea, biguanide, alpha-glucosidase inhibitor, glitazone, dipeptidyl peptidase-4 inhibitor, or sodium-glucose transport protein-2 inhibitor), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and statin usage;

*P*\<0.05 vs. Q1;

*P*\<0.01 vs. Q1;

*P*\<0.001 vs. Q1.

###### 

HGI According to Quartiles of Waist Circumference in Men and Women

  Variable                                                                   Q1       Q2                     Q3                     Q4
  -------------------------------------------------------------------------- -------- ---------------------- ---------------------- ------------------------------------------------------------------------
  Men, HGI range                                                             68--81   82--86                 87--91                 92--107
   Number of subjects                                                        343      414                    389                    423
   Positive HGI                                                                                                                     
    Unadjusted OR                                                            1.000    0.974 (0.731--1.297)   1.256 (0.939--1.681)   1.163 (0.875--1.548)
    Adjusted OR (95% CI)[a](#tfn13-enm-2020-35-2-319){ref-type="table-fn"}   1.000    0.968 (0.726--1.290)   1.246 (0.931--1.668)   1.141 (0.856--1.520)
    Adjusted OR (95% CI)[b](#tfn14-enm-2020-35-2-319){ref-type="table-fn"}   1.000    1.014 (0.740--1.390)   1.349 (0.936--1.945)   1.296 (0.823--2.044)
    Adjusted OR (95% CI)[c](#tfn15-enm-2020-35-2-319){ref-type="table-fn"}   1.000    0.966 (0.697--1.338)   1.264 (0.865--1.849)   1.203 (0.749--1.935)
                                                                                                                                    
  Women, HGI range                                                           60--75   76--80                 81--85                 86--103
   Number                                                                    361      382                    338                    425
   Positive HGI                                                                                                                     
    Unadjusted OR                                                            1.000    1.133 (0.848--1.513)   1.277 (0.947--1.725)   1.547 (1.163--2.062)[e](#tfn17-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[a](#tfn13-enm-2020-35-2-319){ref-type="table-fn"}   1.000    1.113 (0.832--1.488)   1.248 (0.923--1.687)   1.503 (1.127--2.006)[e](#tfn17-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[b](#tfn14-enm-2020-35-2-319){ref-type="table-fn"}   1.000    1.162 (0.852--1.585)   1.345 (0.943--1.921)   1.709 (1.108--2.642)[d](#tfn16-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[c](#tfn15-enm-2020-35-2-319){ref-type="table-fn"}   1.000    1.117 (0.811--1.539)   1.313 (0.908--1.901)   1.669 (1.062--2.630)[d](#tfn16-enm-2020-35-2-319){ref-type="table-fn"}

HGI, hemoglobin glycation index; Q, quartile (Q1 was the lowest quartile); OR, odds ratio; CI, confidence interval.

Adjusted for age and duration;

As in ^a^, and additionally adjusted for BMI;

As in ^b^, and additionally adjusted for systolic blood pressure, exercise status, smoking status, hypoglycemic agent usage (insulin, sulfonylurea, biguanide, alpha-glucosidase inhibitor, glitazone, dipeptidyl peptidase-4 inhibitor, or sodium-glucose transport protein-2 inhibitor), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and statin usage;

*P*\<0.05 vs. Q1;

*P*\<0.01 vs. Q1.

###### 

Association of the Presence of Carotid Artery Plaque with Quartiles of Thigh Circumference in Men and Women

  Variable                                                                   Q1      Q2                                                                       Q3                                                                       Q4
  -------------------------------------------------------------------------- ------- ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------
  Men                                                                                                                                                                                                                                  
   Number of subjects                                                        147     710                                                                      547                                                                      171
   Plaque (+)                                                                                                                                                                                                                          
    Unadjusted OR                                                            1.000   0.664 (0.441--0.983)[d](#tfn22-enm-2020-35-2-319){ref-type="table-fn"}   0.460 (0.303--0.685)[f](#tfn24-enm-2020-35-2-319){ref-type="table-fn"}   0.215 (0.131--0.345)[f](#tfn24-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[a](#tfn19-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.916 (0.593--1.394)                                                     0.899 (0.574--1.389)                                                     0.634 (0.370--1.076)
    Adjusted OR (95% CI)[b](#tfn20-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.708 (0.448--1.103)                                                     0.548 (0.325--0.911)[d](#tfn22-enm-2020-35-2-319){ref-type="table-fn"}   0.304 (0.156--0.586)[f](#tfn24-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[c](#tfn21-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.755 (0.473--1.190)                                                     0.587 (0.345--0.988)[d](#tfn22-enm-2020-35-2-319){ref-type="table-fn"}   0.352 (0.178--0.689)[e](#tfn23-enm-2020-35-2-319){ref-type="table-fn"}
                                                                                                                                                                                                                                       
  Women                                                                                                                                                                                                                                
   Number of subjects                                                        154     572                                                                      569                                                                      217
   Plaque (+)                                                                                                                                                                                                                          
    Unadjusted OR                                                            1.000   0.801 (0.550--1.156)                                                     0.631 (0.434--0.910)[d](#tfn22-enm-2020-35-2-319){ref-type="table-fn"}   0.478 (0.311--0.730)[f](#tfn24-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[a](#tfn19-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.884 (0.596--1.301)                                                     0.860 (0.579--1.269)                                                     0.767 (0.485--1.207)
    Adjusted OR (95% CI)[b](#tfn20-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.818 (0.546--1.218)                                                     0.730 (0.469--1.129)                                                     0.587 (0.335--1.021)
    Adjusted OR (95% CI)[c](#tfn21-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.734 (0.483--1.106)                                                     0.714 (0.454--1.114)                                                     0.590 (0.332--1.041)

Q, quartile (Q1 was the lowest quartile); OR, odds ratio; CI, confidence interval.

Adjusted for age and duration;

As in ^a^, and additionally adjusted for body mass index;

As in ^b^, and additionally adjusted for systolic blood pressure, exercise status, smoking status, hypoglycemic agent usage (insulin, sulfonylurea, biguanide, alpha-glucosidase inhibitor, glitazone, dipeptidyl peptidase-4 inhibitor, or sodium-glucose transport protein-2 inhibitor), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and statin usage;

*P*\<0.05 vs. Q1;

*P*\<0.01 vs. Q1;

*P*\<0.001 vs. Q1.

###### 

Association of the Presence of Carotid Artery Plaque with Quartiles of Waist Circumference in Men and Women

  Variable                                                                   Q1      Q2                     Q3                     Q4
  -------------------------------------------------------------------------- ------- ---------------------- ---------------------- ----------------------------------------------------------------------
  Men                                                                                                                              
   Number of subjects                                                        343     414                    389                    423
   Plaque (+)                                                                                                                      
    Unadjusted OR                                                            1.000   0.950 (0.709--1.273)   0.949 (0.705--1.276)   1.067 (0.796--1.429)
    Adjusted OR (95% CI)[a](#tfn26-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.981 (0.715--1.345)   0.998 (0.725--1.373)   1.207 (0.878--1.658)
    Adjusted OR (95% CI)[b](#tfn27-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.877 (0.618--1.243)   0.826 (0.55--1.239)    0.894 (0.538--1.485)
    Adjusted OR (95% CI)[c](#tfn28-enm-2020-35-2-319){ref-type="table-fn"}   1.000   0.824 (0.572--1.185)   0.734 (0.479--1.122)   0.831 (0.487--1.415)
                                                                                                                                   
  Women                                                                                                                            
   Number of subjects                                                        361     382                    338                    425
   Plaque (+)                                                                                                                      
    Unadjusted OR                                                            1.000   1.321 (0.989--1.765)   1.234 (0.916--1.663)   1.459 (1.1--1.938)[e](#tfn30-enm-2020-35-2-319){ref-type="table-fn"}
    Adjusted OR (95% CI)[a](#tfn26-enm-2020-35-2-319){ref-type="table-fn"}   1.000   1.185 (0.874--1.607)   1.055 (0.77--1.444)    1.217 (0.903--1.64)
    Adjusted OR (95% CI)[b](#tfn27-enm-2020-35-2-319){ref-type="table-fn"}   1.000   1.209 (0.873--1.673)   1.091 (0.752--1.582)   1.290 (0.821--2.027)
    Adjusted OR (95% CI)[c](#tfn28-enm-2020-35-2-319){ref-type="table-fn"}   1.000   1.047 (0.745--1.469)   0.939 (0.635--1.387)   1.039 (0.645--1.675)

Q, quartile (Q1 was the lowest quartile); OR, odds ratio; CI, confidence interval.

Adjusted for age and duration;

As in ^a^, and additionally adjusted for body mass index;

As in ^b^, and additionally adjusted for systolic blood pressure, exercise status, smoking status, hypoglycemic agent usage (insulin, sulfonylurea, biguanide, alpha-glucosidase inhibitor, glitazone, dipeptidyl peptidase-4 inhibitor, or sodium-glucose transport protein-2 inhibitor), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and statin usage;

*P*\<0.05 vs. Q1;

*P*\<0.01 vs. Q1;

*P*\<0.001 vs. Q1.

[^1]: Kap Bum Huh deceased on January 23, 2020
